| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0,0 € | — | — | 0,0 € | — | — | — | 0,0 € | — | 434,6 k € | -24.8% | 578,2 k € | |||||||||||
| Gross margin | 319,9 k € | +0.5% | 318,4 k € | +14.8% | 277,3 k € | +172.0% | 102,0 k € | +74.9% | 58,3 k € | -39.5% | 96,3 k € | -35.1% | 148,4 k € | +6.2% | 139,7 k € | -2.7% | 143,6 k € | -16.3% | 171,6 k € | -11.1% | 193,1 k € | -31.7% | 282,7 k € | |
| EBITDA | 311,2 k € | -1.5% | 316,0 k € | +15.2% | 274,2 k € | +179.8% | 98,0 k € | +70.9% | 57,4 k € | -40.1% | 95,8 k € | -33.7% | 144,4 k € | +8.6% | 133,0 k € | -6.7% | 142,6 k € | -14.6% | 166,9 k € | -4.7% | 175,2 k € | -34.1% | 266,0 k € | |
| Operating profit | 303,0 k € | +1.8% | 297,7 k € | +19.3% | 249,6 k € | +245.5% | 72,2 k € | +55.9% | 46,3 k € | +0.7% | 46,0 k € | -43.8% | 81,9 k € | +12.4% | 72,8 k € | -3.4% | 75,4 k € | -25.7% | 101,5 k € | -7.9% | 110,2 k € | -35.4% | 170,7 k € | |
| Profit/loss | 223,7 k € | +2.2% | 219,0 k € | +22.5% | 178,7 k € | +233.6% | 53,6 k € | +61.7% | 33,1 k € | +4.8% | 31,6 k € | -46.7% | 59,3 k € | +25.7% | 47,2 k € | -4.9% | 49,6 k € | -20.6% | 62,5 k € | -16.9% | 75,3 k € | -25.9% | 101,5 k € | |
| Equity | 30,1 k € | +47.0% | 20,5 k € | 0.0% | 20,5 k € | 0.0% | 20,5 k € | -39.5% | 33,8 k € | +10.2% | 30,7 k € | +27.4% | 24,1 k € | -30.7% | 34,8 k € | -67.7% | 107,6 k € | +85.7% | 57,9 k € | -70.4% | 195,4 k € | +62.7% | 120,1 k € | |
| Total assets | 163,0 k € | -1.0% | 164,7 k € | -9.3% | 181,6 k € | +9.6% | 165,7 k € | +11.5% | 148,6 k € | -9.6% | 164,3 k € | -41.3% | 280,0 k € | -7.9% | 304,0 k € | +0.6% | 302,4 k € | -40.3% | 506,2 k € | +9.8% | 461,2 k € | -15.5% | 545,6 k € | |
| Cash | 68,8 k € | -1.9% | 70,1 k € | -21.2% | 89,0 k € | +25.3% | 71,0 k € | -7.5% | 76,7 k € | +5.5% | 72,7 k € | -46.3% | 135,4 k € | +15.3% | 117,4 k € | +17.1% | 100,3 k € | -60.0% | 250,5 k € | +29.9% | 192,8 k € | -11.5% | 217,9 k € | |
| Debts | 131,9 k € | -7.9% | 143,2 k € | -10.6% | 160,3 k € | +10.5% | 145,1 k € | +26.4% | 114,7 k € | -14.1% | 133,6 k € | -47.8% | 255,9 k € | -4.9% | 269,2 k € | +38.2% | 194,8 k € | -56.5% | 448,3 k € | +68.6% | 265,8 k € | -37.5% | 425,4 k € | |
| Staff | — | — | — | — | — | — | — | — | — | 0,1 | 0,5 | 0,4 | ||||||||||||
Private limited company · Amay · incorporated on 15/10/2013
Private limited company profitable but thinly capitalised.
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure — thin equity (30,1 k €) relative to earnings. The abridged model hides revenue.
European Drug Development Consulting is a Private limited company incorporated in 2013. Its main activity is: Public relations and communication activities. Its registered office is in Amay.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette